Safety pharmacology investigations on the nervous system: An industry survey

Journal of Pharmacological and Toxicological Methods

Volumn 81, Issue , 2016, Pages 37-46

  Authier, Simon ^a   Arezzo, Joseph ^b   Delatte, Marcus S ^c   Kallman, Mary Jeanne ^d   Markgraf, Carrie ^e   Paquette, Dominique ^a   Pugsley, Michael K ^f   Ratcliffe, Sian ^g   Redfern, William S ^h   Stevens, Joanne ^e   Valentin, Jean Pierre ⁱ   Vargas, Hugo M ^j   Curtis, Michael J ^k  

^a SOLVO BIOTECHNOLOGY   (Hungary)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d Kallman Preclinical Consulting   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f PURDUE PHARMA L P   (United States)

^g PFIZER INC   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ UCB PHARMA   (Belgium)

^j AMGEN INC   (United States)

^k ST THOMAS HOSPITAL   (United Kingdom)

more..

Author keywords

Abuse; EEG; Neurological functional observation battery; Safety pharmacology; Seizure; Sleep

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; DRUG; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; ARTICLE; COCULTURE; COGNITIVE DEFECT; COORDINATION DISORDER; DIZZINESS; DRUG ABUSE; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; ELECTROENCEPHALOGRAPHY; FATIGUE; GAIT DISORDER; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HIPPOCAMPAL SLICE; HUMAN; INSOMNIA; IRWIN TEST; NAUSEA AND VOMITING; NERVE CELL CULTURE; NERVE CONDUCTION VELOCITY TEST; NEUROLOGIC EXAMINATION; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; POLYSOMNOGRAPHY; SALIVATION; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TOXICITY TESTING; TREMOR; VISUAL IMPAIRMENT; VOMITING; ADVERSE DRUG REACTION; AGING; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DRUG DEPENDENCE; DRUG EFFECTS; DRUG INDUSTRY; MOUSE; NERVE CONDUCTION; NERVOUS SYSTEM DISEASES; PRECLINICAL STUDY; QUESTIONNAIRE; RAT; SAFETY; SLEEP; STATISTICS AND NUMERICAL DATA;

AGING; ANIMALS; BEHAVIOR, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROENCEPHALOGRAPHY; HUMANS; MICE; NERVOUS SYSTEM DISEASES; NEURAL CONDUCTION; RATS; SAFETY; SEIZURES; SLEEP; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES;

EID: 84992093359     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2016.06.001     Document Type: Article

References (86)

1. Alimoradi, H., Pourmohammadi, N., Mehr, S.E., Hassanzadeh, G., Hadian, M.R., Sharifzadeh, M.,.. Dehpour, A.R., Effects of lithium on peripheral neuropathy induced by vincristine in rats. Acta Medica Iranica 50 (2012), 373–379.
2. Alzheimer's Association, 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11 (2015), 332–384.
3. Anon, Novel new drugs 2014 summary. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf, 2015.
4. Arezzo, J.C., Litwak, M., Zotova, E., Correlation and dissociation of electrophysiology and histopathology in the assessment of toxic neuropathy. Toxicologic Pathology 39:1 (2011), 46–51.
5. Argyriou, A.A., Polychronopoulos, P., Koutras, A., Xiros, N., Petsas, T., Argyriou, K.,.. Chroni, E., Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. European Journal of Cancer Care 16 (2007), 231–237.
6. Arrowsmith, J., Miller, P., Trial watch: Phase II and phase III attrition rates 2011–2012. Nature Reviews Drug Discovery, 12, 2013, 569.
7. Asnis, G.M., Chakraburtty, A., DuBoff, E.A., Krystal, A., Londborg, P.D., et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. Journal of Clinical Psychiatry 60 (1999), 668–676.
8. Ator, N.A., Griffiths, R.R., Principles of drug abuse liability assessment in laboratory animals. Drug and Alcohol Dependence 70 (2003), S55–S72.
9. Authier, S., Paquette, D., Gauvin, D., Sammut, V., Fournier, S., Chaurand, F., Troncy, E., Video-electroencephalography in conscious non-human primate using radiotelemetry and computerized analysis: Refinement of a safety pharmacology model. Journal of Pharmacological and Toxicological Methods 60 (2009), 88–93.
10. Authier, S., Pugsley, M.K., Troncy, E., Curtis, M.J., Arrhythmogenic liability screening in cardiovascular safety pharmacology: Commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies. Journal of Pharmacological and Toxicological Methods 62 (2010), 83–88.
11. Authier, S., Bienvenu, J.G., Tavcar, R., Fournier, S., Schneider, A., Wong, K., Functional observation battery in nonhuman primates with continuous intracerebral infusion. Journal of Pharmacological and Toxicological Methods, 66, 2012, 162.
12. Authier, S., Vargas, H.M., Curtis, M.J., Holbrook, M., Pugsley, M.K., Safety pharmacology investigations in toxicology studies: An industry survey. Journal of Pharmacological and Toxicological Methods 68 (2013), 44–51.
13. Authier, S., Bassett, L., Pouliot, M., Rachalski, A., Troncy, E., Paquette, D., Mongrain, V., Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods 70 (2014), 86–93.
14. Baird, S.J., Catalano, P.J., Ryan, L.M., Evans, J.S., Evaluation of effect profiles: Functional Observational Battery outcomes. Fundamental and Applied Toxicology 40 (1997), 37–51.
15. Bassett, L., Troncy, E., Pouliot, M., Paquette, D., Ascah, A., Authier, S., Telemetry video-electroencephalography (EEG) in rats, dogs and non-human primates: Methods in follow-up safety pharmacology seizure liability assessments. Journal of Pharmacological and Toxicological Methods 70 (2014), 230–240.
16. BCC Research, Therapeutic drugs for central nervous system disorders: Technologies and global markets. http://www.bccresearch.com/report/drugs-central-nervous-system-disorders-phm068a.html, 2010.
17. Berg, S.L., Parsons, D.W., The pharmacogenomics of vincristine-induced neuropathy: On pins and needles. Journal of the American Medical Association Oncology 1:7 (2015), 975–976.
18. Bianchi, R., Brines, M., Lauria, G., Savino, C., Gilardini, A., Nicolini, G., Rodriguez-Menendez, V., et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clinical Cancer Research 12 (2006), 2607–2612.
19. Bobylev, I., Joshi, A.R., Barham, M., Ritter, C., Neiss, W.F., Höke, A., Lehmann, H.C., Paclitaxel inhibits mRNA transport in axons. Neurobiology of Disease 82 (2015), 321–331.
20. Cavaletti, G., Cavalletti, E., Montaguti, P., Oggioni, N., De Negri, O., Tredici, G., Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 18 (1997), 137–145.
21. Cavaletti, G., Fabbrica, D., Minoia, C., Frattola, L., Tredici, G., Carboplatin toxic effects on the peripheral nervous system of the rat. Annals of Oncology 9 (1998), 443–447.
22. Chang, C.H., Yang, Y.H., Lin, S.J., Su, J.J., Cheng, C.L., Lin, L.J., Risk of insomnia attributable to β-blockers in elderly patients with newly diagnosed hypertension. Drug Metabolism and Pharmacokinetics 28 (2013), 53–58.
23. Ciriaco, M., Ventrice, P., Russo, G., Scicchitano, M., Mazzitello, G., Scicchitano, F., Russo, E., Corticosteroid-related central nervous system side effects. Journal of Pharmacology & Pharmacotherapeutics 4:Suppl 1 (2013), S94–98.
24. Cooke, J.R., Loredo, J.S., Liu, L., Marler, M., Corey-Bloom, J., Fiorentino, L.,.. Ancoli-Israel, S., Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Drugs & Aging 23 (2006), 503–511.
25. Curtis, M.J., Abernethy, D.R., Revision of instructions to authors for pharmacology research and perspectives: Enhancing the quality and transparency of published work. Pharmacology Research & Perspectives, 2015, e00106.
26. Curtis, M.J., Bond, R.A., Spina, D., Ahluwalia, A., Alexander, S.P.A., Giembycz, M.A., Gilchrist, A., et al. Experimental design and analysis and their reporting: New guidance for publication in BJP. British Journal of Pharmacology 172 (2015), 2671–2674.
27. Dham, B.S., Hunter, K., Rincon, F., The epidemiology of status epilepticus in the United States. Neurocritical Care 20 (2014), 476–483.
28. Easter, A., Bell, M.E., Damewood, J.R. Jr., Redfern, W.S., Valentin, J.P., Winter, M.J.,.. Bialecki, R.A., Approaches to seizure risk assessment in preclinical drug discovery. Drug Discovery Today 14 (2009), 876–884.
29. Elberly, L.E., Leppik, I.E., Svendsen, K.H., et al. Incident epilepsy/seizure disorder in US nursing homes by predisposing conditions, 2003–2007. Neurology, 74, 2010, A42.
30. European Medicines Agency (EMEA), Guideline on the non-clinical investigation of the dependence potential of medicinal products. EMEA/CHMP/SWP/94227/2004. 2006.
31. European Medicines Agency (EMEA), Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for pediatric indications. EMEA/CHMP/SWP/169215/2005. 2008.
32. Ewart, L., Milne, A., Adkins, D., Benjamin, A., Bialecki, R., Chen, Y., Ericsson, A.C., Gardner, S., Grant, C., et al. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions. Journal of Pharmacological and Toxicological Methods 68 (2013), 30–43.
33. Fonck, C., Easter, A., Pietras, M.R., Bialecki, R.A., CNS adverse effects: From functional observation battery/Irwin tests to electrophysiology. Handbook of Experimental Pharmacology 229 (2015), 83–113.
34. Food and Drug Administration (FDA) Guidance Document, Nonclinical safety evaluation of pediatric drug products. 2006, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD, USA ( http://www.fda.gov/cder/guidance/5671fnl.pdf).
35. Food and Drug Administration (FDA) Guidance for Industry, Assessment of abuse potential of drugs. 2010, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD, USA ( http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm198650.pdf).
36. Gambarotta, G., Ronchi, G., Friard, O., Galletta, P., Perroteau, I., Geuna, S., Identification and validation of suitable housekeeping genes for normalizing quantitative real-time PCR assays in injured peripheral nerves. PloS One, 9(8), 2014, e105601.
37. Gastaut, H., Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 11 (1970), 102–113.
38. Gauvin, D.V., Baird, T.J., A functional observational battery in non-human primates for regulatory-required neurobehavioral assessments. Journal of Pharmacological and Toxicological Methods 58 (2008), 88–93.
39. Gauvin, D.V., McComb, M., Code, R., Dalton, J.A., Baird, T.J., Abuse liability assessment of hydrocodone under current draft regulatory guidelines. Journal of Pharmacological and Toxicological Methods(15), 2015, 00050–00057, 10.1016/j.vascn.2015.05.003 (pii: S1056-8719).
40. Giarola, A., Moscardo, E., Fasdelli, N., Tontodonati, M., Dorigatti, R., Neurobehavioural assessment in pre-clinical species: Rodents, dogs, mini-pigs and monkeys. Journal of Pharmacological and Toxicological Methods, 58, 2008, 151.
41. Gotter, A.L., Winrow, C.J., Brunner, J., Garson, S.L., Fox, S.V., Binns, J., Harrell, C.M., Cui, D., Yee, K.L., et al. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neuroscience, 14, 2013, 90.
42. Gu, Q., Dillon, C.F., Burt, V.L., Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief 42 (2010), 1–8.
43. Hauser, W.A., Annegers, J.F., Kurland, L.T., Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia 34 (1993), 453–468.
44. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nature Biotechnology 32 (2014), 40–51.
45. Himmel, H.M., Safety pharmacology assessment of central nervous system function in juvenile and adult rats: Effects of pharmacological reference compounds. Journal of Pharmacological and Toxicological Methods 58 (2008), 129–146.
46. 3 receptor antagonist. Psychopharmacology 228 (2013), 187–197.
47. Irwin, S., Comprehensive observational assessment: A systematic quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacology 13 (1968), 222–257.
48. Kallman, M.J., Preclinical abuse potential assessment. Handbook of Experimental Pharmacology 229 (2015), 115–130.
49. Klein, S.K., Redfern, W.S., Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report. Journal of Pharmacological and Toxicological Methods 76 (2015), 1–6.
50. Kocer, B., Sucak, G., Kuruoglu, R., Aki, Z., Haznedar, R., Erdogmus, N.I., Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy. Acta Neurologica 109 (2009), 120–126.
51. Koseki, N., Deguchi, J., Yamashita, A., Miyawaki, I., Funabashi, H., Establishment of a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish. Journal of Toxicological Sciences 39 (2014), 579–600.
52. Li, Y., Zhang, H., Kosturakis, A.K., Cassidy, R.M., Zhang, H., Kennamer-Chapman, R.M.,.. Dougherty, P.M., MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy. Brain Behavior Immunology(15), 2015, 00154–00163 (pii: S0889-1591).
53. Lindgren, S., Bass, A.S., Briscoe, R., Bruse, K., Friedrichs, G.S., Kallman, M.J.,.. Pugsley, M.K., Benchmarking safety pharmacology regulatory packages and best practice. Journal of Pharmacological and Toxicological Methods 58 (2008), 99–109.
54. Löscher, W., Hönack, D., Fassbender, C.P., Nolting, B., The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Research 8:3 (1991, Apr), 171–189.
55. Lowenstein, D.H., Alldredge, B.K., Status epilepticus. New England Journal of Medicine 338 (1998), 970–976.
56. Markgraf, C.G., Cirino, M., Meredith, J., Comparison of methods for analysis of functional observation battery (FOB) data. Journal of Pharmacological and Toxicological Methods 62 (2010), 89–94.
57. Melnikova, I., Pain market. Nature Reviews Drug Discovery 9 (2010), 589–590.
58. Metea, M., Litwak, M., Arezzo, J., Assessment of seizure risk in pre-clinical studies: Strengths and limitations of the electroencephalogram (EEG). Journal of Pharmacological and Toxicological Methods(15), 2015, 00039–00048, 10.1016/j.vascn.2015.04.001 (pii: S1056-8719).
59. Moreno, L., Pearson, A.D., How can attrition rates be reduced in cancer drug discovery?. Expert Opinion on Drug Discovery 8 (2013), 363–368.
60. Moscardo, E., Maurin, A., Dorigatti, R., Champeroux, P., Richard, S., An optimized methodology for the neurobehavioural assessment in rodents. Journal of Pharmacological and Toxicological Methods 56:2 (2007, Sep–Oct), 239–255.
61. Moscardo, E., Fasdelli, N., Giarola, A., Tontodonati, M., Dorigatti, R., An optimized neurobehavioural observation battery integrated with the assessment of cardiovascular function in the beagle dog. Journal of Pharmacological and Toxicological Methods 60 (2009), 198–209.
62. Moscardo, E., McPhie, G., Fasdelli, N., Giarola, A., Tontodonati, M., Dorigatti, R., Meecham, K., An integrated cardiovascular and neurobehavioural functional assessment in the conscious telemetered cynomolgus monkey. Journal of Pharmacological and Toxicological Methods 62 (2010), 95–106.
63. Moser, M., Propranolol and newer antihypertensive drugs in the management of hypertension. Advances in Cardiology 26 (1979), 38–43.
64. Moser, P., Wolinsky, T., Castagné, V., Duxon, M., Current approaches and issues in non-clinical evaluation of abuse and dependence. Journal of Pharmacological and Toxicological Methods 63 (2011), 160–167.
65. Mullard, A., Cancer market hits $100 billion. Nature Reviews Drug Discovery, 14, 2015, 373.
66. Nowbar, A.N., Howard, J.P., Finegold, J.A., Asaria, P., Francis, D.P., 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: Statistics from World Health Organisation and United Nations. International Journal of Cardiology 174:2 (2014, Jun 15), 293–298.
67. Palmer, A.M., Alavijeh, M.S., Translational CNS medicines research. Drug Discovery Today 17 (2012), 1068–1078.
68. Pollack, G.M., Shen, D.D., A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. Journal of Pharmacological Methods 13:2 (1985, Apr), 135–146.
69. Porsolt, R.D., Lemaire, M., Dürmüller, N., Roux, S., New perspectives in CNS safety pharmacology. Fundamental & Clinical Pharmacology 16 (2002), 197–207.
70. Pugsley, M.K., Authier, S., Curtis, M.J., Principles of safety pharmacology. British Journal of Pharmacology 154 (2008), 1382–1399.
71. Pugsley, M.K., Authier, S., Towart, R., Gallacher, D.J., Curtis, M.J., Beyond the safety assessment of drug-mediated changes in the QT interval… what's next?. Journal of Pharmacological and Toxicological Methods 60 (2009), 24–27.
72. Quasthoff, S., Hartung, H.P., Chemotherapy-induced peripheral neuropathy. Journal of Neurology 249 (2002), 9–17.
73. Redfern, W.S., Inclusion of safety pharmacology endpoints in repeat-dose toxicity studies. Pugsley, M.K., Curtis, M., (eds.) Principles of safety pharmacology Series: Handbook of experimental pharmacology, vol. 229, 2015, Springer.com, 353–381.
74. Redfern, W.S., Strang, I., Storey, S., Heys, C., Barnard, C., Lawton, K.,.. Valentin, J.P., Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compounds. Journal of Pharmacological and Toxicological Methods 52 (2005), 77–82.
75. Redfern, W.S., Ewart, L.C., Lainée, P., Pinches, M., Robinson, S., Valentin, J.-P., Functional assessments in repeat-dose toxicity studies: The art of the possible. Toxicology Research 2 (2013), 209–234.
76. Schaumburg, H.H., Zotova, E., Raine, C.S., Tar, M., Arezzo, J.C., The caudal nerves: A model system for experimental neuropathies. Journal of the Peripheral Nervous System 15 (2010), 128–139.
77. Teo, S., Evans, M., Ehrhart, J., Brockman, M., Allen, D., Morgan, M.,.. Thomas, S., Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules. Human & Experimental Toxicology 19 (2000), 615–622.
78. Teuns, G.B., Geys, H.M., Geuens, S.M., Stinissen, P., Meert, T.F., Abuse liability assessment in preclinical drug development: Predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models. Journal of Pharmacological and Toxicological Methods 70 (2014), 295–309.
79. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 65:2 (2015), 87–108.
80. Valentin, J.P., Hammond, T., Safety and secondary pharmacology: Successes, threats, challenges and opportunities. Journal of Pharmacological and Toxicological Methods 58 (2008), 77–87.
81. Valentin, J.P., Pollard, C., Lainée, P., Hammond, T., Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines. British Journal of Pharmacology 159 (2010), 25–33.
82. Vargas, H.M., Bass, A.S., Koerner, J., Matis-Mitchell, S., Pugsley, M.K., Skinner, M.,.. Valentin, J.P., Evaluation of drug-induced QT interval prolongation in animal and human studies: A literature review of concordance. British Journal of Pharmacology 172 (2015), 402–411.
83. Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery 14 (2015), 475–486.
84. Wolf, S., Barton, D., Kottschade, L., Grothey, A., Loprinzi, C., Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. European Journal of Cancer 44 (2008), 1507–1515.
85. Wright Willis, A., Evanoff, B.A., Lian, M., Criswell, S.R., Racette, B.A., Geographic and ethnic variation in Parkinson disease: A population-based study of US Medicare beneficiaries. Neuroepidemiology 34 (2010), 143–151.
86. Zotova, E.G., Arezzo, J.C., Non-invasive evaluation of nerve conduction in small diameter fibers in the rat. Physiology Journal, 2013, 2013 (pii: 254789).